Effect of human plasma proteins on spontaneous contractile activity of rat mesenteric portal vein.
This study examines the effect of various plasma proteins from man on the spontaneous contractile activity of the rat portal vein. Albumin, gamma-globulin, alpha-globulin, beta-globulin (the major plasma proteins), and immunoglobulin IgG (the major immunoglobulin present in the gamma-globulin fraction) were obtained commercially. Mesenteric portal vein strips were prepared from rats and placed in a physiological salt solution in muscle baths for the measurement of longitudinal mechanical response. Portal veins exposed to albumin or gamma-globulin showed a dose-dependent increase in the spontaneous activity, whereas those exposed to alpha-globulin or alpha- and beta-globulin together showed a dose-dependent inhibition of spontaneous activity. Immunoglobulin IgG produced a dose-dependent increase in the spontaneous activity similar to that of gamma-globulin. The increased spontaneous activity produced by albumin was not prevented by ouabain but was inhibited by phentolamine. Spontaneous contractile activity was stimulated by albumin in the chemically (6-hydroxydopamine) denervated portal vein. These findings indicate that albumin acts in a manner similar to noradrenaline. The increased spontaneous activity caused by gamma-globulin (IgG) was inhibited by ouabain or verapamil. The effect of IgG was not dependent on alpha-adrenergic, cholinergic, histaminergic, serotoninergic, or renin angiotensin systems nor was it affected by removal of the endothelium. These observations may have implications in the pathophysiology of essential hypertension.
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
G
G
Pillai
M C
MC
Sutter
D000510:Alpha-Globulins / Q000502:physiology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001609:Beta-Globulins / Q000502:physiology; D001798:Blood Proteins / Q000502:physiology*; D002744:Chlorpheniramine / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000502:physiology; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D008642:Mesenteric Veins / Q000502:physiology*; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D010042:Ouabain / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011169:Portal Vein / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D012504:Saralasin / Q000494:pharmacology; D012709:Serum Albumin / Q000502:physiology; D014700:Verapamil / Q000494:pharmacology; D005719:gamma-Globulins / Q000502:physiology
D000510:Alpha-Globulins; D001609:Beta-Globulins; D001798:Blood Proteins; D007074:Immunoglobulin G; D012709:Serum Albumin; D005719:gamma-Globulins; D002744:Chlorpheniramine; D010042:Ouabain; D001285:Atropine; D007650:Ketanserin; D014700:Verapamil; D012504:Saralasin; D010646:Phentolamine